News
Grifols Procleix ArboPlex Assay® erhält die CE-Zertifizierung – der erste und einzige 4-in-1-Nukleinsäuretest zum Nachweis von Arboviren
- Der In-vitro-Nukleinsäuretest von Grifols weist vier Arten von Arboviren nach und trägt dazu bei, das Risiko transfusionsbedingter Infektionen zu verringern
- Arboviren stellen eine wachsende
Brand Messaging and Overlooked Digital Marketing Trends
Edison Investment Research Limited: Edison issues outlook on Oryzon Genomics (ORY)
Edison Investment Research Limited: Edison issues outlook on Laboratorios Farmacéuticos ROVI (ROVI)
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its full-year 2023 financial results.
This press release features multimedia. View the full release
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases
Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, pharmacokinetics,
Why Shares of Grifols Were Up Tuesday
Shares of Grifols (NASDAQ: GRFS) were up 11.1% on Tuesday afternoon, after being up as much as 13.1% earlier in the day. The pharmaceutical company, which makes plasma-derived medicines, released
Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants
Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced a drug
Almirall’s Nine-month 2023 Results:
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.
Financial highlights (€ rounded million)
9M 2023
9M 2022
Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years
43rd Annual Fall Clinical Dermatology Conference
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, today announced results from the long-term extension
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, today announced the presentation of new data on lebrikizumab through 18 abstracts, including two oral
Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis
Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, unveiled new data at the European Association of Dermatology and Venereology Congress 2023 that
Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.
Financial highlights (€ rounded million)
H1 2023
Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis
Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced that Ilumetri® (tildrakizumab) significantly improved wellbeing in patients with
Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing
Psoriasis is a chronic dermatological disease that not only affects the skin but also their mental and social wellbeing. The disease has an impact on all aspects of daily lives and almost 77% of
Almirall announces the pricing and closing of its €200mm non pre-emptive share capital increase
Almirall S.A. (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, has announced today the pricing and closing of its EUR 200,000,000 non-pre-emptive share capital
Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase
Almirall S.A. (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, today announced the launch of a non pre- emptive share capital increase (the “Capital Increase”) for
Almirall’s First Quarter 2023 Results
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its Q1 2023 financial results.
Financial highlights (€ rounded million)
Q1 2023
Almirall’s Full-Year 2022 Results
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2022 financial results today.
Financial highlights (€ rounded million)